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Abstract
Choosing the optimal management strategy for antiplatelet and anticoagulation medications
at the time of cardiac device implantation can be challenging. Simply withholding or reversing
these medications puts patients at risk of subsequent thromboembolic events. Equally, continuing
these medications may unnecessarily increase the risk of bleeding complications. This article
summarizes recent findings and provides compelling evidence challenging current recommen-
dations outlined by various professional organizations. (Cardiol J 2011; 18, 1: 103–109)
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Introduction
The optimal management of antiplatelet and
anticoagulation medications prior to cardiac device
(pacemaker [PM] or implantable cardioverter-
-defibrillator [ICD]) implantation has been the sub-
ject of several recent publications [1–7]. Some of
this attention stems from the pervasive use of new
antiplatelet agents, including thienopyridines (e.g.
clopidogrel, prasugrel and ticlopidine) and direct
thrombin inhibitors (e.g. bivalirudin and arga-
troban). Until recently, little was known about the
risk of bleeding complications in patients taking dual
antiplatelet therapy beyond anecdotal experience.
Additionally, several recent studies have questioned
the practice of heparin bridging, suggesting that it
is not cost-effective, lengthens hospitalization, and
is perhaps less safe, exposing patients to greater
risks of bleeding and thromboembolic complications
during transition periods [8–11].
Our article summarizes recent findings and
provides compelling evidence that challenges cur-
rent recommendations outlined by professional or-
ganizations [12–14].
Normal hemostasis involves a series of com-
plex, well-regulated interactions between the vas-
cular wall, platelets and coagulation cascade, which
are intended to reduce bleeding and promote vas-
cular repair following injury [15]. Antiplatelet and
anticoagulation medications, which exert their ef-
fects by disrupting these steps, can have profound
consequences on periprocedural bleeding compli-
cations.
Most patients referred for cardiac PM or ICD
implantation are taking some form of antiplatelet or
anticoagulation medication. Aspirin and thienopy-
ridines are often prescribed for primary or second-
ary prevention of cardiovascular events such as
myocardial infarction or stroke. Dual antiplatelet
therapy, consisting of aspirin and clopidogrel, is
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universally prescribed following percutaneous cor-
onary interventions (PCI) that involve placement
of either bare metal or drug-eluting stents to reduce
the risk of in-stent thrombosis. With regard to an-
ticoagulants, warfarin is commonly prescribed to
reduce the risk of thromboembolic events in pa-
tients with atrial fibrillation, mechanical prosthetic
valves, previous strokes, reduced left ventricular
systolic function, left ventricular apical thrombus,
and previous deep venous thrombosis or pulmonary
embolism. Heparin is often used to provide short-
term anticoagulation while warfarin is being held or
titrated to therapeutic goal.
From a clinical perspective, defining the opti-
mal periprocedural management of these medica-
tions can be challenging. Simply withholding or re-
versing these medications places patients at risk of
subsequent thromboembolic events, while continu-
ing these medications may unnecessarily increase
the risk of bleeding complications.
The most common bleeding complication fol-
lowing cardiac device implantation is the develop-
ment of a pocket hematoma. In addition to causing
significant patient discomfort, pocket hematomas
increase the risk of pocket infections, prolong hos-
pitalization (because of the need for continued ob-
servation) and expose patients to unprotected pe-
riods while antiplatelet and/or anticoagulation medi-
cations are being withheld [16–18]. The incidence
of pocket hematoma formation varies greatly de-
pending on the periprocedural antiplatelet and an-
ticoagulation medications used, but can exceed 20%
[2, 4, 19]. Studies suggest that as many as 1.0% of
cardiac device implantations require pocket explo-
ration to address ongoing bleeding, thus exposing
patients to a second procedure, increasing hospi-
talization costs, risk of infection, and patient dissatis-
faction [18, 20, 21].
Mechanism of action
Primary hemostasis is mediated by complex
interactions between the vascular wall and plate-
lets, which culminate in the formation of a platelet
plug (Fig. 1) [15, 22]. This process is initiated by
platelet adhesion, which involves the bridging of von
Willebrand factor, present on exposed subendothe-
lial collagen, to glycoprotein (Gp) Ib receptor ex-
pressed on platelets. Platelet activation ensues,
bringing about the expression of GpIIb/IIIa recep-
tors on the platelet surface, and stimulating release
factors that trigger the coagulation cascade. Plate-
let activation is further enhanced by the presence
of adenosine diphosphate (ADP), thromboxane, and
thrombin with platelet-specific receptors. Platelet
aggregation follows, mediated by the cross-linking
of fibrinogen to GpIIb/IIIa receptors. A secondary
hemostatic plug develops following activation of the
coagulation cascade, as the primary platelet plug is
reinforced by fibrin cross-linking.
Antiplatelet and anticoagulation medications
disrupt hemostasis by targeting specific sites along
this cascade (Fig. 1). Aspirin affects platelet acti-
vation and aggregation by irreversibly inhibiting
cyclooxygenase (COX) enzyme, thereby blocking
the formation of thromboxane A2 [23, 24].
Thienopyridines similarly affect platelet activation
and aggregation, but they do so by irreversibly in-
Figure 1. Overview of hemostasis [12].
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hibiting ADP binding to the platelet ADP receptor
(P2Y12) [24]. Thus, the mechanism of action of as-
pirin and clopidogrel affects the expression of
GpIIb/IIIa receptors on platelets and inhibits the re-
lease of factors that stimulate the coagulation cascade.
The primary target of heparin is disruption of
the coagulation cascade [25]. By potentiating the
activity of antithrombin III, heparin indirectly inhib-
its the activity of coagulation factors IIa (thrombin),
IXa, Xa, XIa, and XIIa. Of these, factors Xa and IIa
are inhibited to the greatest extent by the heparin-
-antithrombin III complex, thus explaining the anti-
coagulation properties of heparin. Heparin also in-
fluences platelet plug formation as reflected by pro-
longed bleeding times. Binding of heparin to von
Willebrand factor diminishes platelet adhesion, and
platelet aggregation is reduced by inhibiting throm-
bin-mediated activation of platelets. Importantly,
the action of heparin is broad, affecting several dif-
ferent steps in the establishment of hemostasis.
Warfarin interferes with the synthesis of vita-
min K-dependent coagulation factors, notably Fac-
tors II, VII, IX, X, and proteins C and S [26]. The
anticoagulation efficacy of warfarin declines when
the international normalized ratio (INR) is less than
2.0 and is essentially eradicated when the INR is
less than 1.5 [27]. The effect of warfarin is much
more specific than heparin and inhibits only the co-
agulation cascade.
In summary, aspirin, clopidogrel and, to some
extent, heparin, affect the development of the prima-
ry hemostatic plug by disrupting platelet adhesion and
aggregation. Warfarin and heparin block reinforce-
ment of the platelet plug by fibrin cross-linking.
Current antiplatelet/anticoagulant
management strategies
Ideally, the strategy chosen to manage anti-
platelet and anticoagulation medications should re-
duce the risk of procedure-related bleeding com-
plications without unnecessarily increasing the risk
of thromboembolic events. Perioperative guidelines
published by the ACC/AHA support continuing low-
-dose aspirin monotherapy for non-cardiac surgical
procedures, noting only a small increase in proce-
dure-related bleeding (relative risk 1.5), without
substantially increasing the severity of bleeding
complications or perioperative mortality [12].
A similar recommendation is provided for those re-
ceiving monotherapy with clopidogrel or ticlopidine.
Suggestions pertaining to the management of
dual antiplatelet therapy are less definitive. This is
largely due to uncertainty regarding the appropriate
length of treatment following PCI to minimize early
and late in-stent thrombosis. In general, the guide-
lines support delaying elective non-cardiac surgery
until the following endpoints are reached [12]:
Dual antiplatelet therapy should be continued
for a minimum of:
— 14 days following balloon angioplasty;
— 30–45 days following bare metal stent implan-
tation;
— 12 months or more following uncomplicated on-
label use of drug-eluting stent.
Once the recommended duration of dual anti-
platelet therapy is complete, the guidelines support
holding clopidogrel for at least five days while con-
tinuing aspirin in the periprocedural period.
Management strategies for anticoagulation
medications are briefly discussed in the atrial fibril-
lation and valvular heart disease guidelines [13, 14].
The authors of these guidelines suggest that warfarin
may be safely held in low-risk patients (Table 1),
allowing the INR to drift below 1.5 without initiat-
ing heparin. However, in those patients deemed
high-risk, the guidelines support holding anticoagu-
lation therapy and administering either unfractionat-
ed or low-molecular weight heparin once INR < 2.0.
Heparin should then be held for 4–6 hours preop-
eratively and restarted as soon as possible from
a surgical perspective.
In practice, physicians appear to be following
these recommendations. deBono et al. [5] carried
Table 1. Assessment of risk of thromboembolic events.
Risk of thromboembolic events
Low-moderate High
Mechanical aortic valves Prosthetic mitral and/or tricuspid valves
Atrial fibrillation without prior CVA/TIA Atrial fibrillation with prior CVA/TIA
Current treatment for DVT, PE, LAA or LV thrombus
Documented hypercoagulable conditions*
*Factor V Leiden, prothrombin G2021A mutations, protein C, S or antithrombin III deficiencies, antiphospholipid antibody syndrome; CVA — cerebro-
vascular accident; TIA — transient ischemic attack; DVT — deep venous thrombosis; PE — pulmonary embolus; LAA — left atrial appendage;
LV — left ventricular
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out an illuminating questionnaire-based study to
determine periprocedural anticoagulation manage-
ment strategies among physicians implanting car-
diac devices in the United Kingdom. Of the respon-
dents, only 11% of implanting physicians would
continue anticoagulation in patients with mechani-
cal mitral valves undergoing cardiac device implan-
tation, despite the growing evidence that suggests
it is safe to do so. The remaining 89% said that they
would hold warfarin for £ three days and institute
heparin bridging either as unfractionated or low-
-molecular weight heparin.
Importantly, however, results from our study,
and those of others, question these recommenda-
tions, suggesting that heparin ‘bridging’ may actu-
ally be more harmful to patients than maintaining
warfarin therapy throughout the perioperative pe-
riod. A recent prospective study by our group [28]
demonstrated an increase in thromboembolic and
bleeding complications in patients randomized to
warfarin interruption prior to cardiac device implan-
tation. Notably, there were no thromboembolic or
bleeding complications in those continued on war-
farin.
Results from recent investigations
Antiplatelet therapy
We retrospectively assessed the risk of deve-
loping bleeding complications in patients undergo-
ing cardiac device implantation. The frequency of
bleeding complications in controls who were not
receiving any antiplatelet (or anticoagulant) thera-
py was 1.6% [1]. The likelihood of developing
a bleeding complication doubled in patients receiv-
ing aspirin therapy alone (1.6% vs 3.9%; p = 0.078)
and more than quadrupled in those receiving dual
antiplatelet therapy (1.6% vs 7.2%; p = 0.004).
In a similar retrospective analysis, Thal et al. [4]
reported pocket hematomas occurring in 1.2% of
patients receiving aspirin only, 2.6% of patients con-
tinued on warfarin (mean INR 1.9 ± 0.6), and, re-
markably, 20% of patients receiving dual antiplate-
let therapy. Kutinsky et al. [2] reported hematoma
formation in 18.3% of patients treated with clopi-
dogrel, while no hematomas occurred in patients who
had clopidogrel held for four or more days.
Interestingly, when major bleeding complica-
tions (defined as the need for blood transfusion,
pocket revision, cardiac tamponade requiring emer-
gent pericardiocentesis or prolonged hospitaliza-
tion) and minor bleeding complications (defined as
small hematoma or local ecchymosis not requiring
treatment) were combined, Przybylski et al. [6]
noted a higher frequency in those receiving dual
antiplatelet therapy when compared to aspirin alone
(24.5% vs 13.9%; p = 0.06). Importantly, however,
they found no difference in major bleeding compli-
cations between the two groups when assessed
separately (3.6% vs 3.8%; p = 0.7, respectively),
which led them to conclude that dual antiplatelet
therapy does not increase the risk of major bleed-
ing complications.
Anticoagulant therapy
Several case series published in the late 1990s
challenged the use of heparin ‘bridging’ for cardiac
device implantation [9–11]. Goldstein et al. [9] were
among the first to report their experience, implant-
ing devices in 37 patients continued on warfarin at
the time of device implantation. They found no dif-
ference in wound-related or wound-unrelated com-
plications between patients receiving warfarin
(mean INR 2.5) and controls (mean INR 1.1). Al-
-Khadra [10] reported similar findings in 47 patients
with a mean INR 2.3 (range 1.5–3.1) at device im-
plantation. Only one patient in the anticoagulated
group developed a small (4 × 3 cm) hematoma that
resolved spontaneously.
Giudici et al. [11] published a large retrospec-
tive cohort consisting of 1,025 patients referred for
device implantation, comparing 470 anticoagulated
patients against 555 non-anticoagulated patients.
The rates of bleeding complications were similar
between the anticoagulated (mean 2.6 ± 1.0) and
non-anticoagulated groups (INR < 1.5). Hematomas
occurred in 2.6% of the anticoagulated patients
(nine in-hospital and three late hematomas), and
2.2% in the non-anticoagulated patients (again, nine
in-hospital and three late hematomas). Patients in
both groups were treated conservatively with pres-
sure dressings. It should be noted, however, that
two patients in the anticoagulation group did require
pocket exploration for ongoing bleeding concerns.
Alteration in medical therapy (i.e. discontinuation
of heparin or warfarin) occurred in rare instances.
Importantly, one patient in the non-anticoagulated
group suffered a stroke, but it is unclear if this pa-
tient was previously on warfarin therapy for throm-
boembolism prophylaxis.
Shortly thereafter, Wiegand et al. [3] reported
their findings on the predictors of intraoperative
bleeding or pocket hematoma formation in 3,164
patients who had PM or ICD implantation, genera-
tor replacement or lead revision. In this study, as-
pirin use was associated with a 3.1% incidence of
bleeding. The combination of aspirin plus thienopy-
ridine markedly increased the incidence of bleeding,
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to 21.7%. This study also assessed the use of hep-
arin. Patients receiving anticoagulation with phen-
procoumon, a derivative of coumarin, had the medi-
cation held until INR drifted below 1.5. Heparin
bridging was initiated once the INR < 2.0. Post-
operatively, anticoagulation was re-established by
heparin infusion, titrated to a partial thromboplastin
time of 40–60 s, initiated either with a bolus immedi-
ately following the procedure or without a bolus start-
ing within 12 hours of the procedure. As expected,
the incidence of hematomas was significantly higher
in those receiving heparin with bolus compared to
those without a bolus (28.1% vs 12.0%; p = 0.05).
The timing of heparin reinitiation following
device implantation was assessed by Michaud et al.
[19]. They performed a prospective randomized
study comparing the incidence of pocket hemato-
mas in 49 patients requiring anticoagulation. Pa-
tients were randomized to receive intravenous he-
parin either six or 24 hours after PM implantation.
Pocket hematomas occurred in 20% of patients re-
ceiving intravenous heparin, irrespective of the ini-
tiation time, compared to 4% of patients continued
on warfarin therapy alone and 2% not receiving any
anticoagulation therapy. Pocket hematomas were
noted in 23% of patients started on heparin six
hours following PM implantation, vs 17% initiated
at 24 hours, which was not statistically significant.
Patients treated with heparin were also more like-
ly to remain in the hospital for longer, averaging 3.6
± 2.9 days vs 2.3 ± 1.1 days when on warfarin alone
and 2.5 ± 2.5 days when receiving no therapy.
Heparin bridging also contributed to increased
hematoma formation and prolonged hospitalization
in patients undergoing cardiac resynchronization
therapy implantation [7]. In this retrospective
study, patients were divided into three groups:
— warfarin group: continued on warfarin such that
the INR = 2–3;
— heparin bridging group: pre-implant — warfa-
rin held for four days, unfractionated heparin
started when INR £ 2; post-implant — unfrac-
tionated heparin restarted six hours later;
— control group: warfarin held for four days.
Warfarin was restarted in all patients on the
evening of the day cardiac device implantation took
place. Once again, the use of heparin bridging sig-
nificantly increased the rate of hematoma formation
(controls: 4.1%; warfarin group: 5.0%; heparin
group: 20.7%; p = 0.03) and was associated with
longer stays (controls: 1.6 ± 1.6; warfarin group:
2.9 ± 2.7; bridging 3.7 ± 3.2; p < 0.001).
Updated antiplatelet/anticoagulant
management strategies
Based on our findings, and those of others, we
have altered our management strategies for both
antiplatelet and anticoagulation regimens (Figs. 2, 3).
In most cases, we recommend holding antiplatelet
medications, such as aspirin or thienopyradines (i.e.
clopidogrel), for a period of 5–7 days, specifically
when prescribed for primary prevention of cardio-
vascular events. The management of these medica-
Figure 2. Algorithm for pre-procedure management of antiplatelet medications; CVE — cardiovascular events;
*Off-label: bifurcating lesions, ovelapping stents, and/or multiple stents; †see text.
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tions becomes less clear when used for secondary
prevention. The annual rates of death and myocardial
infarction in patients with known coronary artery
disease can range from as low as 0.5% in low-risk
patients to greater than 25% in high-risk popula-
tions [12]. Additionally, the cumulative risk of re-
current stroke or death ranged from 41–46% in
patients who had had a previous stroke [29]. Given
these uncertain and worrying projections, we feel
it is prudent to continue antiplatelet therapy dur-
ing the perioperative period when prescribed for
secondary prevention, particularly in high-risk pa-
tients (Fig. 2).
Unquestionably, perioperative dual antiplate-
let therapy increases the absolute risk of bleeding
complications from 7–22% [1, 3, 4]. The absolute
risk of bleeding complications is also increased with
aspirin use, but to a lesser extent, ranging from 1–
–4%. Thus, it seems reasonable to consider hold-
ing clopidogrel for a period of five days while con-
tinuing aspirin in patients receiving dual antiplate-
let therapy who are at low risk of thromboembolic
events.
Assuming dual antiplatelet therapy is being
used to prevent in-stent thrombosis following PCI,
we would define a low-risk population as being those
who met the minimum recommended duration of
therapy (see above). High-risk patients consist of
those who have not completed the recommended
duration of therapy and those with ‘off-label’ indica-
tions for stent placement [30] (e.g. bifurcating le-
sions, overlapping stents, and/or multiple stents). It
is our opinion that dual antiplatelet therapy should
be continued throughout the perioperative period in
these high-risk individuals with an awareness of in-
creased bleeding complications rates.
With regard to anticoagulation therapy, we can-
not justify the practice of heparin ‘bridging’. Rath-
er, we recommend holding warfarin for a period of
3–5 days to allow the INR to drift below 1.5 in those
patients receiving chronic warfarin therapy who are
at low-to-moderate risk of thromboembolic events
(Table 1). Conversely, patients deemed high-risk
should be continued on warfarin throughout the
perioperative period. It is reasonable either to hold
or reduce one to two doses of warfarin prior to the
procedure to allow the INR to trend downwards.
However, sub-therapeutic INRs should be avoided
to prevent unnecessary non-anticoagulated periods
that increase the risk of thromboembolic events.
The only notable exceptions here are those patients
who undergo simultaneous lead extraction, some-
thing which should only be performed when the INR
is below 1.5.
Conclusions
The perioperative use of either dual antiplate-
let therapy or heparin ‘bridging’ significantly in-
creases the risk of procedure-related bleeding com-
plications following cardiac device implantation, and
unnecessarily exposes patients to non-anticoagulat-
ed periods. Recent studies challenge current pro-
fessional guidelines. To optimize patient care, im-
planting physicians must pay particular attention to
the various management strategies being used, and
tailor them as needed on a patient-by-patient basis
to minimize periprocedural complications.
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